Genmab — December 2023
-
The Lancet Haematology
@TheLancetHaem
Won Seog Kim presents data from the EPCORE NHL-5 dose escalation and expansion trial testing the bispecific antibody epcoritamab plus lenalidomide in patients with r/r DLBCL. One DLT (neutropenia) was observed (primary endpoint). ORR was 71.9% and CR was 53.1% #ASH23 https://twitter.com/TheLancetHaem/status/1733924588126666831 -
Genmab har lovende resultater med kræfthåb i svært behandlelig lymfekræft https://www.proinvestor.com/investornyt/1088770/genmab-har-lovende-resultater-med-kraefthab-i-svaert-behandlelig-lymfekraeft
-
Multiple Myeloma Hub
@MM_Hub
CONGRESS | #ASH23 | Efstathios Kastritis
@uoaofficial
discusses the safety and efficacy results of daratumumab monotherapy in ND 3B LC AL from the EMN22 trial. 6-month OS rate was 65% and a haematological response in 77.5% of pts -- AL Amyloidosis--
https://twitter.com/MM_Hub/status/1733959437386215879 -
-
-
Gid mine Genmabber også blev handlet på den platform, hvor "Genmab stiger efter gode resultater"...
-
the abstracts of the posters are all you will get i think, need to be lucky to find someone posting a picture on twitter...
https://ash.confex.com/ash/2023/webprogram/start.html#srch=words|epcoritamab|method|and|pge|1|byDayany|any|bySessionTypeP|1|bySymposiumany|any|byAudienceany|any
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
